Citation Impact
Citing Papers
Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
2014
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
2012
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States
2008 Standout
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
2013
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells
2012
Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer
2011
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
2001
Crosstalk between TGF-β signaling and the microRNA machinery
2012
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
Breast cancer
2016 Standout
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
2014
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Substrate-Specific Kinetics of Dicer-Catalyzed RNA Processing
2010 StandoutNobel
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Stromal cells in tumor microenvironment and breast cancer
2012
Maximizing clinical benefit with trastuzumab
2004
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Discovery of microRNAs and other small RNAs in solid tumors
2010
Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features
2003
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
2005
MicroRNAs in cancer: biomarkers, functions and therapy
2014 Standout
Biology of Natural Killer Cells
1989 Standout
CA 15-3: Uses and limitation as a biomarker for breast cancer
2010
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Lack of Exercise Is a Major Cause of Chronic Diseases
2012 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Regulation of hematopoiesis by T lymphocytes and natural killer cells
1987
Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base
2006
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer
2010
Physical Activity and Pregnancy
2010
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Platinum Compounds in the Treatment of Advanced Breast Cancer
2001
Cisplatin: The first metal based anticancer drug
2019 Standout
The relevance of the TGF-β Paradox to EMT-MET programs
2013
TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology
2016 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Development of novel therapeutic strategies that target HIF-1
2006 StandoutNobel
Protein therapeutics: a summary and pharmacological classification
2007 Standout
p21 gene codon 31 arginine/serine polymorphism: Non‐association with endometriosis
2001
Breast cancer metastasis: markers and models
2005 Standout
What makes a good case–control study?
2002 Standout
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma
2011 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
2009 Standout
Unusual T cell proliferations and neutropenia in rheumatoid arthritis: comparison with classical Felty's syndrome
1984
Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity
2000
Regulation of human blood erythroid burst-forming unit (BFU-E) proliferation by T-lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies
1982
Direct Serum Assay for MicroRNA-21 Concentrations in Early and Advanced Breast Cancer
2010
Inhibition of bone marrow colony formation by human natural killer cells and by natural killer cell-derived colony-inhibiting activity.
1985
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo.
1985
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
2014 StandoutNobel
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
The role of autologous helper and suppressor T cells in the regulation of human granulopoiesis
1982
Large granular lymphocytes have a promoting activity on human peripheral blood erythroid burst-forming units
1985
Metaplastic Breast Cancer: Clinical Features and Outcomes
2005
Chronic Inflammation and Cytokines in the Tumor Microenvironment
2014 Standout
Cells with Fc gamma receptors from normal donors suppress granulocytic macrophage colony formation
1982
Works of Antonio Durando being referenced
Metaplastic breast carcinoma: pathology and clinical outcome.
2003
TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
2008
A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer
2004
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
2013
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma
2003
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
2010
Flow Cytometry in Breast Cancer
1998
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
2008
Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse
2001
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients
2006
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest–Mammella Intergruppo (GONO-MIG) Group
2007
Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study.
1997
Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
2000
Generation of CFU-C/suppressor T cells in vitro: an experimental model for immune-mediated marrow failure
1981
Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy
2006
Exercise and Pregnancy
1992